HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
41 - 50 of 193
Comorbidity of Autism and Epilepsy

Dr. William Gaetz. has partnered with pediatric neurologist, Dr. Eric Marsh and neuropsychologist, Dr. Lisa Blaskey to better understand Epilepsy in children who have an Autism Spectrum Disorder (ASD).
Contrast-Enhanced Ultrasound Evaluation of Bowel Perfusion in Necrotizing Enterocolitis
The goal of this study is to develop ultrasound techniques that assess blood supply to the intestines using an investigational contrast agent. Our hope is to contribute to early diagnosis and improved outcomes.
Contrast-Enhanced Ultrasound Evaluation of Hypoxic Ischemic Injury
The goal of this HIE (Hypoxic Ischemic Encephalopathy) Study is to develop ultrasound techniques for detecting impaired blood supply to the brain using an investigational contrast agent.
Copanlisib in Solid Tumors or Lymphoma
The purpose of this study is to find out what is the right dose of copanlisib in children and adolescents, and if your disease responds to this new drug.
CP-SMC Pilot Study

The purpose of this study is to assess deficits in movement and coordination in children with cerebral palsy (CP) and without.
Craniofacial Pathologies
The Craniofacial Pathologies biobank is a research study collecting and storing reamining surgical specimens from the cranium and face from diagnosed patients at CHOP with a congenital craniofacial anomaly.
CrCEST MRI in Mitochondrial Disease
Study focusing on non-invasive MRI procedures to measure biological activity within leg muscles of individuals, including both healthy volunteers and those with mitochondrial disease.
CTX and Idiopathic Bilateral Cataracts in Pediatric Patients

CTX is typically a highly progressive disease, with case reports of symptoms that first appear at any time from birth through adulthood and then worsen over time.
CureGN Study

Cure Glomerulonephropathy Network (CureGN) is a multi-year study of 2,400 children and adults with four rare glomerular (kidney) diseases at over 50 centers in the US, Canada, and Italy.
Daratumumab for T-cell ALL

CHOP, in collaboration with Janssen Research & Development, is conducting a study for children and young adults up to 30 years old, with relapsed or refractory precursor T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. This clinical trial is adding the study drug, daratumumab, to a standard relapse chemotherapy regimen.